Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
BrainChild Bio’s initial CAR T-cell therapy program will focus on advancing ongoing clinical trials evaluating safety and efficacy in pediatric brain tumors. SEATTLE--(BUSINESS WIRE)--Seattle Children ...
Three weeks ago, on January 5, Graphite Bio announced a voluntary pause of their Phase I/II CEDAR clinical trial of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) after observing ...
bbT369, 2seventy bio’s investigational novel CD79a/CD20 dual targeting CBLB gene edited CAR T cell therapy demonstrates promising anti-lymphoma activity in preclinical models bbT369 is the first novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results